Key result
Combination lipid therapy recommended over high-intensity statins as first-line care for very high-risk patients.
Advocates for the upfront use of combination lipid-lowering therapy as the standard of care in very high-risk patients to rapidly and effectively achieve guideline-recommended LDL-C goals.
May support upfront combination therapy in very high-risk patients; hypothesis-generating and requires validation in prospective trials.
Combination lipid-lowering therapy as first line strategy in very high-risk patients. Combination lipid-lowering therapy as first line strategy in very high-risk patients.
No takes yet. Share an insight, caveat, or question.
Ray et al. (2021) conducted an editorial in Very high-risk atherosclerotic cardiovascular disease. Combination lipid-lowering therapy vs. Statin monotherapy was evaluated. Combination lipid-lowering therapy, rather than high-intensity statin monotherapy, is proposed as a first-line standard of care to achieve LDL cholesterol goals in very high-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: